An observational study in Melanoma, sponsored by Bristol-Myers Squibb. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-11.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Melanoma by Bristol-Myers Squibb — 3 open to participants now, 9 under way, 3 of them phase 3. Melanoma · Bristol-Myers Squibb.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 27th largest by enrollment of the 32 observational ones that give a count, is one of 12 that started in 2016, is one of 32 observational ones, and was the 83rd registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →3 of the 111 studies in Melanoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Belgium, Canada and 10 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada and 5 more countries
Ages 18+
Bristol-Myers Squibb · Sites in India
Ages 12+
By country, each count listing its studies:
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 33 · Phase 3 23 · Phase 4 1
First in 2002; this study’s year is marked. 12 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is below the median of 187 across 489 observational studies indexed under Melanoma.
Median enrollment 107 across the 75 interventional studies, 366 across the 32 observational. Of the 90 that completed or were terminated, 41 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Melanoma by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04550247Bristol-Myers SquibbA Prospective Non-Interventional Study in Participants Receiving Nivolumab in Adjuvant Setting for Resected Melanoma in Real-World Conditions in France | 2027-03-15 |
Add it to your calendar (.ics) → With an account.
Among the 111 studies in Melanoma by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study of late physical, psychological and social effects in patients treated with ipilimumab for advanced (stage IV or unresectable stage III) melanoma.
Patients with advanced melanoma who survived at least 2 years and were treated with ipilimumab between 2011 and 2015 in one of the specified melanoma centers in the Netherlands.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort
Other: Non-Interventional
24 to 36 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2014 in one of the 14 melanoma centers in the Netherlands
Other: Non-Interventional
36 to 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2013 in one of the 14 melanoma centers in the Netherlands
Other: Non-Interventional
Greater than 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab between 2011 and 2012 in one of the 14 melanoma centers in the Netherlands
Other: Non-Interventional
Non-Interventional
This study also gives Ipilimumab. No intervention listed here names it: that was found by reading the record.
European Organisation for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ C30)
EORTC QLQ-C30 is a self-reported, 30-item generic questionnaire developed to assess 15 domains: global health status scale, five functional scales (physical, role, emotional, cognitive, and social functioning) and nine symptom scales (fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).
Time frame: Baseline up to 3 years
Hospital Anxiety and Depression Scale (HADS)
14-item questionnaire assesses symptoms of mood disturbance, yielding separate scale scores for anxiety and depression, as well as a total score
Time frame: Baseline up to 3 years
Multidimensional Fatigue Inventory (MFI)
Fatigue will be assessed with the Multidimensional Fatigue Inventory (MFI)
Time frame: Baseline up to 3 years
Cancer Worry Scale (CWS)
8-item questionnaire will be used to assess the prevalence of cancer-specific distress in melanoma survivors and in healthy controls
Time frame: Baseline up to 3 years
European Organisation for Research and Treatment of Cancer Quality Of Life (EORTC QLQ) module for sexual health
Sexual health will be assessed with the European Organisation for Research and Treatment of Cancer Quality Of Life (EORTC QLQ) module for sexual health
Time frame: Baseline up to 3 years
Functional Assessment of Cancer Therapy-Melanoma questionnaire (FACT-M)
51-item measurement of quality of life
Time frame: Baseline up to 3 years
EuroQOL-5D (EQ-5D) survivors
Generic health status will be assessed with the EuroQOL-5D (EQ-5D) survivors
Time frame: Baseline up to 3 years
Impact of Cancer Questionnaire (IOCv2)
81 items that present statements regarding specific impacts of cancer to which respondents indicate their level of agreement from 1 (strongly disagree) to 5 (strongly agree). Seventy items apply to all survivors, 3 to currently employed respondents, 4 to respondents not currently partnered, and 4 to currently partnered respondents
Time frame: Baseline up to 3 years
Work Ability Index questionnaire (WAI)
13-item questionnaire developed to obtain survivors' experiences with return to work and work performance
Time frame: Baseline up to 3 years
EORTC information module (EORTC QLQINFO25)
Information needs will be assessed with the EORTC information module (EORTC QLQINFO25)
Time frame: Baseline up to 3 years
Ran from Dec 2016 to primary completion in Jun 2020, 42 months.
Of 59 industry-sponsored observational studies under Melanoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 80. This study's 42 months is close to that.
Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.